

MIFEPRISTONE

This Policy Statement was developed by the Executive Committee of The Society of Obstetricians and Gynaecologists of Canada (SOGC) and approved by its Council.

The anti-progesterone steroid mifepristone has been developed, tested, and approved for use in several European countries and the USA. The Society of Obstetricians and Gynaecologists of Canada (SOGC) has supported a woman's right to choose safe abortion services and in 1991 supported the introduction of mifepristone into Canada for clinical trials, and now supports its clinical use. The use of such medication for terminating early pregnancy constitutes a significant medical and public health gain and has received medical acceptability in Europe and the USA.

Therefore, the SOGC supports the approval and availability of mifepristone and other anti-progestins, as well as their appropriate prostaglandin counterparts, for appropriate research and clinical use in Canada.

The SOGC urges Health Canada to work with professional organizations and industry to make this product available to Canadian women.

This policy statement replaces Policy Statement No. 10 dated September 1992.

J Obstet Gynaecol Can 2003;25(3):235.

Key Words

Mifepristone, RU-486, early termination